4.3 Article

Neuroprotective effect of resveratrol on rotenone-treated C57BL/6 mice

Journal

NEUROREPORT
Volume 28, Issue 9, Pages 498-505

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNR.0000000000000789

Keywords

dopamine; iron; Parkinson's disease; resveratrol; rotenone

Categories

Funding

  1. National Foundation of Natural Science of China [81430024, 31571054]
  2. National Program of Basic Research - Ministry of Science and Technology of China [2011CB504102]
  3. Excellent Innovative Team of Shandong Province
  4. Taishan Scholars Construction Project

Ask authors/readers for more resources

The aim of the present study was to investigate whether resveratrol could reduce nigral iron levels to prevent the degeneration of dopaminergic neurons in the substantia nigra (SN) of C57BL/6 mice induced by rotenone. Parkinson's disease (PD) is an age-related neurodegenerative disorder; elevated iron levels in the SN participate in neuronal death in PD. Resveratrol is a kind of polyphenolic compounds and possess antioxidant, anticancer, and anti-inflammatory biological functions. Although many research groups have investigated the neuroprotective effects of resveratrol against PD, the precise mechanisms underlying its beneficial effects on dopaminergic neuron are poorly defined. In this study, rotenone-treated mice were used to examine neuroprotective roles of resveratrol in PD. Sixty-four adult C57BL/6 mice were divided into four groups: vehicle control mice, rotenone mice, resveratrol-treated rotenone mice, resveratrol mice. In the present study, we found that chronic administration of rotenone significantly induced motor coordination impairment and increased iron levels and dopaminergic neuron loss in SN in mice. Resveratrol administration significantly protected mice from rotenone-induced motor coordination impairment, elevated iron levels, and dopaminergic neuronal loss. Our results show that resveratrol can elicit neuroprotective effects on rotenone-induced parkinsonism through reducing nigral iron levels. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available